Abstract: Some embodiments of the present disclosure relate to roofing systems. In some embodiments, the roofing system includes a deck, a roofing material, and an underlayment configured to be positioned between the roofing material and the deck. In some embodiments, the underlayment comprises a foil layer and an adhesive layer that is attached to the foil layer and configured to be attached to the deck. Methods of manufacturing roofing systems are also disclosed.

Abstract: Non-limiting embodiments of the present disclosure relate to a method comprising: obtaining asphalt shingle waste (ASW) and performing grinding, screening, and separating steps on the ASW. In some embodiments, granules are removed from the ASW. In some embodiments, the method transforms ASW into ASW powder. In some embodiments, the ASW powder is formed into a plurality of briquettes. In some embodiments, at least one of: the ASW powder, the plurality of briquettes, or any combination thereof is fed into a mixing process that results in an ASW powder filled coating. In some embodiments, the ASW powder is formed into an adhesive composition.

Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. In various embodiments, such polypeptides may be used to treat companion animals, such as canines, felines, and equines.

Abstract: Some embodiments of the present disclosure relate to roofing systems. In some embodiments, the roofing system includes a deck, a roofing material, and an underlayment configured to be positioned between the roofing material and the deck. In some embodiments, the underlayment comprises a foil layer and an adhesive layer that is attached to the foil layer and configured to be attached to the deck. Methods of manufacturing roofing systems are also disclosed.

Abstract: Provided are various embodiments relating to variant asparaginase polypeptides with enhanced stability, pharmacodynamics, and/or reduced immunogenicity. The variant asparaginase polypeptides may be used as therapeutics in mammals, including human, canines, felines, and equines.

Abstract: Non-limiting embodiments of the present disclosure relate to a method comprising: obtaining asphalt shingle waste (ASW) and performing grinding, screening, and separating steps on the ASW. In some embodiments, granules are removed from the ASW. In some embodiments, the method transforms ASW into ASW powder. In some embodiments, the ASW powder is formed into a plurality of briquettes. In some embodiments, at least one of: the ASW powder, the plurality of briquettes, or any combination thereof is fed into a mixing process that results in an ASW powder filled coating. In some embodiments, the ASW powder is formed into an adhesive composition.

Abstract: A roofing system includes a roofing membrane. The roofing membrane has a surface energy of 40 mN/m or less. The roofing system includes a roofing substrate. The roofing system includes an adhesive disposed between the roofing membrane and the roofing substrate. The adhesive includes a styrenic block copolymer. The styrenic block copolymer is present in an amount of 0.5 wt. % to 30 wt. % based on a total weight of the adhesive. The adhesive includes asphalt. The asphalt is present in an amount of 70 wt. % to 99.5 wt. % based on the total weight of the adhesive. A ratio of the styrenic block copolymer to the asphalt in the adhesive is 1:11 to 1:3.

Abstract: Some embodiments of the present disclosure relate to roofing systems including a substrate and adhesive formulations that are free of asphalt or substantially free of asphalt. Some embodiments of the present disclosure relate to methods of making one or more adhesive formulations that are free of asphalt or substantially free of asphalt. Some embodiments of the present disclosure relate to systems utilizing one or more adhesive formulations that are free of asphalt or substantially free of asphalt.

Abstract: Provided are various embodiments relating to IL13R/IL4R contiguous polypeptides and IL13R/IL4R heterodimeric proteins from companion animal species and that bind to IL13 and/or IL4, including long-acting contiguous polypeptides and heterodimeric proteins. Such heterodimeric proteins can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: Some embodiments of the present disclosure relate to roofing systems including a substrate and adhesive formulations that are free of asphalt or substantially free of asphalt. Some embodiments of the present disclosure relate to methods of making one or more adhesive formulations that are free of asphalt or substantially free of asphalt. Some embodiments of the present disclosure relate to systems utilizing one or more adhesive formulations that are free of asphalt or substantially free of asphalt.

Abstract: A roofing system includes a roofing membrane. The roofing membrane has a surface energy of 40 mN/m or less. The roofing system includes a roofing substrate. The roofing system includes an adhesive disposed between the roofing membrane and the roofing substrate. The adhesive includes a styrenic block copolymer. The styrenic block copolymer is present in an amount of 0.5 wt. % to 30 wt. % based on a total weight of the adhesive. The adhesive includes asphalt. The asphalt is present in an amount of 70 wt. % to 99.5 wt. % based on the total weight of the adhesive. A ratio of the styrenic block copolymer to the asphalt in the adhesive is 1:11 to 1:3.

Abstract: Provided are various embodiments relating to caninized TNF? antibodies and caninized NGF antibodies. Such antibodies can be used in methods to treat canines with inflammatory conditions, such as inflammatory bowel disease and/or in methods to treat canines with pain, such as osteoarthrititic pain, back pain, cancer pain, and/or a neuropathic pain.

Abstract: Some embodiments of the present disclosure relate to roofing composites. In some embodiments, the roofing composite includes a first layer having a top surface. In some embodiments, the top surface of the first layer comprises a first embossed surface portion, a second embossed surface portion, and a flat surface portion between the first and second embossed surface portions. In some embodiments, the flat surface portion is between the first and second embossed surface portions. In some embodiments, the roofing composite is configured to attach to a roof structure, such as a roof deck. Methods of forming roofing composited are also disclosed.

Abstract: Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4/IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.

Abstract: Non-limiting embodiments of the present disclosure relate to a method comprising: obtaining asphalt shingle waste (ASW) and performing grinding, screening, and separating steps on the ASW. In some embodiments, granules are removed from the ASW. In some embodiments, the method transforms ASW into ASW powder. In some embodiments, the ASW powder is formed into a plurality of briquettes. In some embodiments, at least one of: the ASW powder, the plurality of briquettes, or any combination thereof is fed into a mixing process that results in an ASW powder filled coating. In some embodiments, the ASW powder is formed into an adhesive composition.

Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.

Abstract: Non-limiting embodiments of the present disclosure relate to a method comprising: obtaining asphalt shingle waste (ASW) and performing grinding, screening, and separating steps on the ASW. In some embodiments, granules are removed from the ASW. In some embodiments, the method transforms ASW into ASW powder. In some embodiments, the ASW powder is formed into a plurality of briquettes. In some embodiments, at least one of: the ASW powder, the plurality of briquettes, or any combination thereof is fed into a mixing process that results in an ASW powder filled coating. In some embodiments, the ASW powder is formed into an adhesive composition.

Abstract: A roofing system includes a roofing membrane. The roofing membrane has a surface energy of 40 mN/m or less. The roofing system includes a roofing substrate. The roofing system includes an adhesive disposed between the roofing membrane and the roofing substrate. The adhesive includes a styrenic block copolymer. The styrenic block copolymer is present in an amount of 0.5 wt. % to 30 wt. % based on a total weight of the adhesive. The adhesive includes asphalt. The asphalt is present in an amount of 70 wt. % to 99.5 wt. % based on the total weight of the adhesive. A ratio of the styrenic block copolymer to the asphalt in the adhesive is 1:11 to 1:3.

Abstract: Provided are various embodiments relating to long-acting anti-IL31 antibodies binding to canine IL31 and/or feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.